<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Helpful Thoughts - Medium]]></title>
        <description><![CDATA[Thoughts at the intersection of healthcare, sustainability and business from @jacobbrody. - Medium]]></description>
        <link>https://medium.com/helpful-thoughts?source=rss----c53c82626dca---4</link>
        <image>
            <url>https://cdn-images-1.medium.com/proxy/1*TGH72Nnw24QL3iV9IOm4VA.png</url>
            <title>Helpful Thoughts - Medium</title>
            <link>https://medium.com/helpful-thoughts?source=rss----c53c82626dca---4</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Thu, 19 Nov 2026 16:37:49 GMT</lastBuildDate>
        <atom:link href="https://medium.com/feed/helpful-thoughts" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[Give Me Some Sugar — How Health System Joint Ventures Can Make Diabetes Care Sustainable]]></title>
            <link>https://medium.com/helpful-thoughts/give-me-some-sugar-how-health-system-joint-ventures-can-make-diabetes-care-sustainable-e997aef7d8f3?source=rss----c53c82626dca---4</link>
            <guid isPermaLink="false">https://medium.com/p/e997aef7d8f3</guid>
            <category><![CDATA[private-equity]]></category>
            <category><![CDATA[chronic-disease]]></category>
            <category><![CDATA[healthcare-innovations]]></category>
            <category><![CDATA[diabetes]]></category>
            <category><![CDATA[healthcare]]></category>
            <dc:creator><![CDATA[Jacob Brody]]></dc:creator>
            <pubDate>Wed, 21 Jun 2023 12:45:48 GMT</pubDate>
            <atom:updated>2023-06-21T16:29:35.413Z</atom:updated>
            <content:encoded><![CDATA[<h3><strong>Give Me Some Sugar — How Health System Joint Ventures Can Make Diabetes Care Sustainable</strong></h3><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*Dr6Xea_wvJ-0xpOYd5cnhw.png" /></figure><p><strong>INTRODUCTION</strong></p><p>When I was diagnosed with type 1 diabetes at 13, I visited my endocrinologist every 3 months. Now I struggle to schedule two appointments each year. Despite incredible strides in care technology, access to quality diabetes care has declined. Instead of personalized care, there is an ever-increasing admin burden and a nagging feeling that the healthcare system doesn’t care about your health.</p><p>Endocrinologists treat a number of conditions, most notably diabetes. Despite the high demand for endocrinology services, health systems often struggle to provide adequate resources for endocrinology clinics to meet demand. This is a multifaceted issue involving factors such as billing processes, reimbursement rates, administrative workload, and a nationwide shortage of endocrinologists. Despite the surging demand for endocrinology, pharmaceutical and device manufacturers capture the windfall profits; healthcare providers face squeezed practice economics and crushing administrative burdens.</p><p>While PE-backed models have emerged in highly procedural specialties like <a href="https://www.medpagetoday.com/special-reports/exclusives/103144">cardiology</a>, gastroenterology, dermatology and podiatry, we’ve seen no such innovation in endocrinology. Practice profitability in endocrinology is elusive. Typical PE approaches for healthcare services aren’t effective without the support of profitable, high-volume, high-revenue procedures within the specialty. The low compensation and poor provider experience drive a provider shortage just as diabetes rates explode.</p><p>The way to improve diabetes care is to partner with health systems in a joint venture structure. By leveraging the local scale and brand of the health system, the JV can receive above-market reimbursement rates while getting instant credibility with local providers. Instead of being perennially under-resourced, a joint venture can leverage private capital to expand access to care while a referral network of hundreds-thousands of health system providers is a built-in source of low-cost patient acquisition.</p><p>The JV structure could turn endocrinology’s weaknesses into strengths. Diabetes treatment is heavily reliant on medical devices for diagnostics and pharmacotherapy for care. A number of different revenue generating services can be targeted towards pharmaceutical and medical device companies or payors. Opportunities for increased revenues and gross margins may be achieved through various methods such as larger patient panels and virtual care. Diabetes care is an excellent fit for virtual care programs including video visits, principal care management, chronic care management, and remote physiological / therapeutic monitoring.They can be staffed by a combination of health system employees and remote staff at a lower cost than traditional practices. If practices are more profitable and leverage lower cost staff for wraparound care than they will increase pay for endocrinologists who anchor the care team. This will make endocrinology a more attractive specialty as patients get better care and physicians will get more support with administrative burdens..</p><p>Improved practice economics can be correlated with improved access and quality of care. There are about 5000 diabetes patients for each practicing endocrinologist in the United States, leading to longer wait times. Higher compensation will attract more medical students and residents to endocrinology and they can care for more patients if they have less soul-crushing paperwork. Health equity programs can be sustainably launched in partnership with health system 340b pharmacy discount programs, a unique resource for non-profit health systems that <a href="https://www.statnews.com/2016/11/01/pharmaceutical-federal-drug-discount-program/">has been deployed successfully at health systems nationwide</a>. A JV model can improve profitability, reduce provider burnout and improve access to comprehensive diabetes care.</p><p><strong>THE PROBLEM</strong></p><p>A significant reason health systems might not allocate adequate resources to endocrinology clinics is the nature of the specialty itself. The financial model of healthcare, in general, leans towards specialties that have more procedures to bill for, as these often yield higher returns. Fundamentally, endocrinologists provide care at low reimbursement rates compared to surgical specialties, while requiring far more unpaid admin work to get care approved. The return on investment for endocrinology can appear to be less attractive by comparison because it relies more on medical management through medications and lifestyle modifications rather than procedures.</p><p>For instance, patients often require expensive medications like insulins or GLP 1 receptor agonists, and some require medical devices such as Continuous Glucose Monitors (CGMs) and insulin pumps. All these interventions frequently require prior authorizations from insurance companies while not providing substantial revenue sources for the health practice. <a href="https://www.ama-assn.org/system/files/prior-authorization-survey.pdf">An AMA survey</a> found that doctors spend an average of 14 hours per week on prior authorization tasks, and given the nature of endocrine treatments, it’s likely that endocrinologists are saddled with even more of this type of work. This is a significant administrative burden that diverts time from patient care and adds another layer of complexity to an already intricate specialty. The costs associated with managing diabetes are considerable but the profits are made by pharmaceutical and medical device companies.</p><p>Compounding these issues is a significant shortage of endocrinologists. <a href="https://www.aamc.org/data-reports/workforce/report/physician-specialty-data-report">According to American Medical Association data</a>, there are only 8,246 practicing endocrinologists in the US. This number pales in comparison to the demand, with an alarming ratio when considering the 37 million diabetes patients alone.</p><p>This situation creates a self-reinforcing cycle. The high administrative workload and lower compensation prospects decrease the appeal of the specialty, leading to fewer new endocrinologists. This, in turn, increases the workload on the existing endocrinologists, making the specialty even less attractive. Improving the provider experience within the health system will prove hard when that system and all of its infrastructure is built for episodic care funded by procedures.</p><p><strong>THE SOLUTION</strong></p><p>Spinout health system’s endocrinology practices into joint ventures managed by a new private company (EndoX). The spinout would leverage the existing endocrinologists in the practice as well as the health systems contracts with payors. EndoX would leverage its own EMR and integrate tools that would enable quality, personalized care and optimize clinical + administrative workflows.</p><p>EndoX’s technology-enabled suite of services would substantially reduce administrative overhead, improving provider experience and practice profitability. In addition to health system staff, a joint venture would leverage remote virtual staff like dietitians and certified diabetes educators to deliver nutrition and behavioral/coaching programs. Leveraging tools built by entities such as the diabetes non-profit Tidepool, the practice can visualize patient data from all of the CGM and insulin pump makers directly within their workflows. An affiliated EndoX subsidiary would develop additional revenue streams based on pharmaceutical and medical device company partnerships involving prior authorization, adherence management, data services, and copay assistance.</p><p>EndoX would build out a managed services organization to manage the joint venture and its clinical operations. All of the provider and operations workflows would be built from scratch to support diabetes care. The use of continuous care models would concurrently improve patient outcomes while also increasing patient retention, provider utilization, and practice profit margins. The Integrated prior authorization and medication adherence services would provide additional revenue streams while reducing up to 14–20 hours of unpaid administrative time per doctor, per week.</p><p>Private equity investors could capitalize the EndoX holdco, co-owning the venture with a chosen management team. Each health system partner would have its own joint venture structure managed by EndoX with care providers employed and credentialed by the health system partner and loaned to the EndoX practice. Additional care providers including doctors, dietitians, and certified diabetes educators would be employed by a friendly physicians group that would sub-contract with the health system. These employees would also be credentialed by each of the health systems which they are contracted with.</p><p><strong>REVENUE STREAMS</strong></p><p><em>HEALTHCARE SERVICES</em></p><p>FEE FOR SERVICE — Endocrinologists and other providers would continue to use the appropriate category 1 CPT codes to bill for services. The practice can also utilize remote physiological monitoring and other remote care related codes to improve patient care and increase revenue.</p><p><em>PHARMACEUTICAL COMPANY SERVICES</em></p><p>Endocrinology has a unique set of high cost treatments that support adherence management businesses selling into pharmaceutical and medical device company partners. There are few other practice areas with similar characteristics treating chronic disease with expensive drugs where the treatment course is ongoing. Other practice areas that could support similar initiatives include rheumatology (expensive biologics) and cardiology (beta blockers and statins).</p><p>PRIOR AUTHORIZATION AS A SERVICE — The MSO incorporates a novel approach to prescription prior authorizations. By setting up a separate, dedicated unit for negotiating partnerships between diabetes pharmaceutical and medical device companies, the MSO can conduct these authorizations with patients’ insurance carriers for a fee. Low-skilled staff and generative AI are delegated initial PAs, while RNs and generative AI handle subsequent PA denial appeals in consultation with the MD. This strategy offers an efficient solution to a growing concern. Direct integration into the joint venture’s EMR offers specialized processes for each drug in collaboration with the eight PBMs that control 99 percent of the PBM market. By eliminating roughly 10 hours per week in prescriber time spent on prior authorizations, this approach adds capacity for roughly 960 additional half-hour appointments annually per prescriber. In addition, PAs are significantly more likely to be handled continuously and quickly given the dedicated workforce. In turn, this significantly improves access to care and practice profitability simultaneously while also supporting better patient outcomes.</p><p>ADHERENCE MANAGEMENT<em> </em>— Endocrinology has a unique set of high cost treatments that support adherence management businesses selling into pharmaceutical and medical device company partners. There are few other practice areas with similar characteristics treating chronic disease with expensive drugs where the treatment course is ongoing. Cardiologists won’t get paid by drug companies to ensure adherence to beta blockers or statins. Pharmaceutical companies will pay for programs that ensure patients take their medications because every month that a patient takes their medication means hundreds or thousands of dollars in revenue to pharmaceutical manufacturers. Medicare advantage plans will also fund medication adherence programs since it greatly improves their star rating, increasing revenue. These programs need to be carefully vetted with legal an constructed in a way that does not implicate medicare anti-kickback statutes. Joint Venture care providers are already working with patients to help them adhere to their pharmacotherapy regimen, so this revenue comes with little additional expense or workload and is easily supported by the lower-paid, non-licensed staff via the MSO. Generally speaking, companies can earn $200 to $400 per patient, per year by successfully implementing and coordinating these adherence management programs (which also support better outcomes for the patients).</p><p>DATA SERVICES — Anonymized patient data demonstrating the efficacy of medications helps pharmaceutical companies negotiate with PBMs and employers for coverage as well as get medications approved for new indications, increasing the market size. Because of this, pharmaceutical companies will pay $200 to $400 per patient, per year in order to secure data that the JV already has without additional work to support the pharmaceutical products.</p><p>COPAY ASSISTANCE — By working on copay assistance programs with pharmaceutical companies like Novo Nordisk and Eli Lilly or medical device companies like Dexcom or Insulet, the Joint Venture can lower costs for patients and pharmaceutical companies. By administering copay assistance programs in specific ways that don’t involve the PBMs, patients can hit their deductibles and out-of-pocket max sooner. Since PBMs pay a greater share of the expense for medications including those used in the treatment of Type 1 and Type 2 Diabetes, this allows budgets for copay assistance to go farther and save the pharmaceutical companies as much as $3,000 per patient. Depending on the structure of the program this, the JV or MSO could earn an additional $100 to $200 per patient, per year.</p><p>CLINICAL TRIAL PARTICIPANT RECRUITING — The cost of clinical trials can be significant, with pivotal trials potentially reaching into the hundreds of millions of dollars. Delays in these trials can be particularly costly, <a href="https://pharmasols.com/news/april-2021/the-cost-of-delaying-a-trial/">with daily costs falling anywhere between $600,000 to $8 million</a>, primarily due to recruitment and retention challenges. Thus, collaborations with health system-affiliated practices can be strategically valuable for efficient patient sourcing and reducing potential delays. With the all in recruitment cost averaging over $6k per patient, <a href="https://mdgroup.com/blog/the-true-cost-of-patient-drop-outs-in-clinical-trials/">according to an MD Group analysis of FDA studies</a>, revenue could run upwards of $2,500 per participant sourced.</p><p><em>POTENTIAL ADDITIONAL BUSINESS LINES</em></p><p>In addition to the fee for service clinic and pharmaceutical company services businesses there are other opportunities to build new business lines. A JV could create affordable alternatives for self-insured employer and government plan sponsors which eliminate PBM rebates or take advantage of the 340b Pharmacy Program for notable discounts on prescription drugs (certain popular diabetes medications offer massive discounts). Bundled programs for type 1 and type 2 diabetes are especially viable in conjunction with 340b discounts. Value based care programs selling into payors, employers and reinsurers are also opportunities, especially when targeted at patient populations presenting with uncontrolled diabetes nearing end-stage renal failure.</p><p><strong>CLOSING THOUGHTS</strong></p><p>While the standard private equity model won’t work in Endocrinology, it is uniquely well suited to health system joint-ventures. On the practice level, it solves the problems of unpaid administrative overhead and the lack of profit-making procedures to fund endocrinology salaries and wraparound. By creating revenue streams from services that the pharmaceutical and medical device companies benefit from, EndoX can help endocrinology practices capture more of the value they create. The shift to a longitudinal model with remote supporting providers like dietitians and CDEs increases margins while improving care.</p><p>Innovative business models like these are difficult to impossible to implement in most health systems, while an EndoX JV model would retain the benefits of health system affiliation while getting the freedom to access outside capital and technological know-how. Health systems would benefit from such programs by reducing the cost of care delivery while expanding access. They would retain the patients and increase their referrer base, resulting in additional downstream referrals to high revenue like bariatric surgery and fertility. EndoX JVs could also substantially increase 340b pharmacy revenues. This could make up for the significant revenue loss that occurred when drug manufacturers terminated discounts for drugs distributed by contract pharmacies, like Walgreens or CVS.</p><p>Most important of all, patients benefit. Providers can access their data and collaborate with them on figuring out solutions that work in their everyday real lives. Patients and providers have a reduced administrative burden, with dedicated personnel aided by customized workflows handling prior authorization services. Patients get improved care coordination and increased access to CDEs and RDs via virtual care. Patients don’t have to wait 3–12 months for an appointment with their current provider or struggle to find a new one who will take them as a patient.</p><p>What joint ventures cannot solve is our broken healthcare system. Diabetes sucks because you’re constantly being asked to jump through hoops to justify care that you need. As a patient with multiple chronic diseases, there is constant anxiety that my treatments might not be covered. On top of managing a complex condition, one must become an expert in the administrative processes of the healthcare industry in order to advocate for oneself in a system that is designed to obstruct access to care. Without better alignment of incentives in our healthcare system, optimizing care for chronic diseases like diabetes, let alone preventing them, will remain a challenge. This is especially true for more vulnerable populations who don’t have the time or resources to effectively advocate for themselves.</p><p>Feel free to reach out to me on Twitter <a href="http://www.twitter.com/jacobbrody">@jacobbrody</a>, via <a href="https://www.linkedin.com/in/jacobbrody/">LinkedIn</a> or <a href="/service/mailto:jacob@helpful.vc">via email</a>. A special thanks to my friends and colleagues for your edits and ideas that made this post possible.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=e997aef7d8f3" width="1" height="1" alt=""><hr><p><a href="https://medium.com/helpful-thoughts/give-me-some-sugar-how-health-system-joint-ventures-can-make-diabetes-care-sustainable-e997aef7d8f3">Give Me Some Sugar — How Health System Joint Ventures Can Make Diabetes Care Sustainable</a> was originally published in <a href="https://medium.com/helpful-thoughts">Helpful Thoughts</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[A Simple Explanation Of AI & Machine Learning]]></title>
            <link>https://medium.com/helpful-thoughts/a-simple-explanation-of-ai-machine-learning-aec845a59ff8?source=rss----c53c82626dca---4</link>
            <guid isPermaLink="false">https://medium.com/p/aec845a59ff8</guid>
            <category><![CDATA[machine-learning]]></category>
            <category><![CDATA[technology]]></category>
            <category><![CDATA[machine-learning-ai]]></category>
            <dc:creator><![CDATA[Jacob Brody]]></dc:creator>
            <pubDate>Tue, 03 Jan 2017 18:30:40 GMT</pubDate>
            <atom:updated>2017-01-03T18:29:48.330Z</atom:updated>
            <content:encoded><![CDATA[<iframe src="https://cdn.embedly.com/widgets/media.html?src=https%3A%2F%2Fwww.youtube.com%2Fembed%2FTjnFOhwDAYM%3Ffeature%3Doembed&amp;url=http%3A%2F%2Fwww.youtube.com%2Fwatch%3Fv%3DTjnFOhwDAYM&amp;image=https%3A%2F%2Fi.ytimg.com%2Fvi%2FTjnFOhwDAYM%2Fhqdefault.jpg&amp;key=d04bfffea46d4aeda930ec88cc64b87c&amp;type=text%2Fhtml&amp;schema=youtube" width="854" height="480" frameborder="0" scrolling="no"><a href="https://medium.com/media/fadeadc94809cc0601858a0fb281fa49/href">https://medium.com/media/fadeadc94809cc0601858a0fb281fa49/href</a></iframe><p>I was watching an interview with Eric Schmidt, Executive Chairman of Alphabet, and I thought his explanation of AI at 17 minutes and 38 seconds into the interview was particularly nuanced while being easy to understand.</p><p>If you’re looking for a thoughtful explanation for how AI and machine learning works this is a good way to spend about 4 minutes.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=aec845a59ff8" width="1" height="1" alt=""><hr><p><a href="https://medium.com/helpful-thoughts/a-simple-explanation-of-ai-machine-learning-aec845a59ff8">A Simple Explanation Of AI &amp; Machine Learning</a> was originally published in <a href="https://medium.com/helpful-thoughts">Helpful Thoughts</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
    </channel>
</rss>